Compare Cenovus Energy Inc (CVE) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Philip Morris International Inc. — how do they compare? Cenovus Energy Inc trades at $31.39 (market cap $57.90B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 5.4× Cenovus Energy Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Philip Morris International Inc. for 85 Days on average.
| CVE | PM | |
|---|---|---|
Market Cap | $57.90B | $312.50B |
Volume | 7,863,588 | 5,517,172 |
Sector | Energy | Consumer Staples |
52-Week High | $33.92 | $200.50 |
52-Week Low | $15.85 | $144.33 |
Typical Hold Time | 46 Days | 85 Days |
Enterprise Value | $63.84B | $355.62B |
Dividend Yield | 1.97% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 2.81% with bullish technical momentum. The stock shows strong fundamentals with a P/E of 12.43 and EV/EBITDA of 6.17, trading near 52-week highs. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. Operating cash flow remains robust at $8.23B despite negative net cash flow in 2025. Analyst consensus is mixed with 40.7% buy ratings amid positive media coverage highlighting growth potential.
CVE presents a compelling value opportunity with attractive valuation metrics and improving profitability. The main investment thesis centers on earnings growth recovery and operational efficiency gains. Key risks include oil price volatility and execution challenges in capital expenditure management. Institutional ownership trends and recent analyst upgrades support a cautiously optimistic outlook for medium-term appreciation.
Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.
The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
